European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis [Hematologic Malignancy]

Conclusion IgM AL amyloidosis is a distinct clinical entity. Low-risk disease can be defined by combining cardiac involvement with novel prognostic markers. Deeper hematologic responses translate into improved outcomes, yet deep responses remain dismally poor, which highlights the urgent need for novel therapies.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Tags: Diagnosis & Staging, Diagnosis & Staging Hematologic Malignancy Source Type: research